# COVID-19 Research Methods Resources

**URL:** <https://discourse.datamethods.org/t/covid-19-research-methods-resources/3143>\
**Category:** design\
**Tags:** covid-19\
**Created:** [March 28, 2020, 11:21am UTC](https://discourse.datamethods.org/t/covid-19-research-methods-resources/3143 "2020-03-28T11:21:06Z")\
**Posts on this page:** 1\
**Showing post:** 5

<div class="post-metadata">

**Author:** ![davidcnorrismd](https://discourse.datamethods.org/user_avatar/discourse.datamethods.org/davidcnorrismd/32/3502_2.png) [@davidcnorrismd](https://discourse.datamethods.org/u/davidcnorrismd)\
**Post date:** [March 29, 2020, 4:45pm UTC](https://discourse.datamethods.org/t/covid-19-research-methods-resources/3143/5 "2020-03-29T16:45:47Z")

</div>

Kudos to you and your team for performing this service, Lawrence!

In [this post](https://discourse.datamethods.org/t/fully-sequential-bayesian-clinical-trial-design-for-in-hospital-treatment-of-covid-19/3129/9) on a parallel discussion board, I highlight a recent paper that suggests opportunities for serial quantification of viral load and IgG & IgM serology. Notably, the viral RNA specimens were obtained from posterior oropharyngeal saliva rather than by the more invasive and hazardous swabs. What is your sense of the feasibility and _clinical_ utility of (and thus motivation for) collecting such serial samples routinely? Is there any prospect for such data to appear in your CPAC warehouse? What time-series would you expect to prove most useful?

---

_[View the full topic](https://discourse.datamethods.org/t/covid-19-research-methods-resources/3143)._